17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Bala-Cynwyd, Pennsylvania 19004, United States
CABA, C1425, Argentina
Córdoba, 5000, Argentina
Cheng Du Shi, 610041, China
Wuhan, 430032, China
Torino, 10126, Italy
Funabashi Shi, 273 8588, Japan
Chungcheongbuk Do, 28644, South Korea
Jeollanam-do, 58128, South Korea